TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Medicinova ( (MNOV) ) has provided an update.
On July 30, 2025, MediciNova, Inc. entered into a Standby Equity Purchase Agreement with YA II PN, LTD., allowing the company to sell up to $30 million of its common stock over 36 months. This agreement provides MediciNova with financial flexibility, although it is subject to conditions such as stockholder approval and compliance with Nasdaq rules, potentially impacting its market operations and investor relations.
The most recent analyst rating on (MNOV) stock is a Buy with a $9.00 price target. To see the full list of analyst forecasts on Medicinova stock, see the MNOV Stock Forecast page.
More about Medicinova
MediciNova, Inc. operates in the biopharmaceutical industry, focusing on the development and commercialization of innovative small molecule therapeutics. The company primarily targets unmet medical needs in the fields of neurology, respiratory diseases, and liver diseases.
Average Trading Volume: 24,203
Technical Sentiment Signal: Sell
Current Market Cap: $64.99M
For detailed information about MNOV stock, go to TipRanks’ Stock Analysis page.